3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Original title: Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug eluting stents. Reference: El-Hayek G et al. Am J Cardiol. 2014; Epub ahead of print. This meta-analysis examined the data of four randomized and controlled studies (EXCELLENT, PRODIGY, RESET y OPTIMIZE) including 8157 patients receiving sirolimus, paclitaxel, everolimus or zotarolimus<a href="https://solaci.org/en/2014/06/24/3-to-6-months-of-dual-antiplatelet-after-des-reduced-bleeding-and-did-not-raise-mortality-or-infarction/" title="Read more" >...</a>

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following Resolute zotarolimus-eluting stent implantation. Reference: Silber S, Kirtane AJ, Belardi JA, et al. Eur Heart J. 2014; Epub ahead of print. Dual antiplatelet aggregation optimal time after implantation of a new generation drug-eluting stent (DES) is still discussed. This<a href="https://solaci.org/en/2014/02/25/at-least-one-month-of-antiplatelet-seems-sufficient-after-a-zotarolimus-eluting-stent/" title="Read more" >...</a>

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor during 12 months in patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), to prevent events such as MI and stent thrombosis.  This was a multicenter, placebo controlled, double blind study to determine whether ticagrelor alone,<a href="https://solaci.org/en/2024/04/10/acc-2024-ultimate-dapt-trial/" title="Read more" >...</a>

La clave para tratar strokes: saber cuando detenerse

Predictors of Stroke at 30 Days and 6 Months After TAVR

While the rate of stroke has decreased since the early days of transcatheter aortic valve replacement (TAVR), it remains non-negligible, reaching up to 1%-3% at 30 days. As TAVR progressively expands to low-risk populations and younger patients, identifying risk factors for patient selection and management in stroke prevention becomes crucial. While researchers have identified predictors<a href="https://solaci.org/en/2023/12/11/predictors-of-stroke-at-30-days-and-6-months-after-tavr/" title="Read more" >...</a>

La complejidad de la angioplastia puede definir el tiempo de doble antiagregación

Optimal Duration of DAPT with Oral Anticoagulation After PCI?: 1 Month vs. 3 Months

While the benefits of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor are recognized, its primary complication is the occurrence of bleeding events, which negatively impact patient morbidity and mortality. Additionally, about 10% of patients undergoing percutaneous coronary intervention (PCI) are on oral anticoagulant therapy, which significantly increases the risk of bleeding when<a href="https://solaci.org/en/2023/11/23/optimal-duration-of-dapt-with-oral-anticoagulation-after-pci-1-month-vs-3-months/" title="Read more" >...</a>

TCT 2023 | COMPARE 60/80 HBR TRIAL

This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT).  A total 747 patients were recruited, 368 received PCI with the ultrathin Superflex stent with 60 µm struts (SUF), and 364 received the Terumo Tansei with 89 µm struts (SF). Primary end point was NACE at<a href="https://solaci.org/en/2023/10/30/tct-2023-compare-60-80-hbr-trial-2/" title="Read more" >...</a>

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one month (1,426 patients), followed by ticagrelor monotherapy for 12 months, while the other group received DAPT with ASA and ticagrelor during 12 months (1,424 patients). This study was<a href="https://solaci.org/en/2023/10/30/tct-2023-t-pass-trial-asa-and-ticagrelor-in-acute-coronary-syndrome/" title="Read more" >...</a>

TCT 2023 | The WATCH-TAVR Study

In the TVT registry, around 40% of the patients eligible for transcatheter aortic valve replacement (TAVR) had atrial fibrillation, and there were high levels of adverse events after starting anticoagulant treatment, especially with oral anticoagulants (VKAs), primarily due to bleeding. The purpose of this study was to assess the feasibility, safety, and efficacy of combined<a href="https://solaci.org/en/2023/10/27/tct-2023-the-watch-tavr-study/" title="Read more" >...</a>

OBSERVANT II: Post TAVR 30-Day and 6-Month Stroke Predictors

Despite stroke rate has declined since the early days of transcatheter aortic valve replacement (TAVR), it remains significant, reaching 1% to 3% 30 days after procedure. Since TAVR has seen a progressive expansion to the low risk and young populations, identifying risk factors in patient selection and management is crucial for us to prevent stroke. <a href="https://solaci.org/en/2023/10/20/observant-ii-post-tavr-30-day-and-6-month-stroke-predictors/" title="Read more" >...</a>

ESC 2023 | STOPDAPT-3

Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown to reduce bleeding events without increased cardiovascular events vs. standard DAPT, according to guidelines.  However, the rate of major bleeding within the first month after procedure remains significant when using these strategies.  The use of aspirin-free therapies (ASA)<a href="https://solaci.org/en/2023/08/29/esc-2023-stopdapt-3-2/" title="Read more" >...</a>